Last updated on November 2018

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations


Brief description of study

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Clinical Study Identifier: NCT02864992

Contact Investigators or Research Sites near you

Start Over

Acya Bizieux

Centre Hospitalier D partemental Les Oudairies
La Roche sur Yon, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.